Bioventus (BVS) Cash from Discontinued Operations (2022 - 2023)
Bioventus posted quarterly Cash from Discontinued Operations of 2169000.0 for Q2 2023, down 70.65% on a QoQ basis from 1271000.0 in Q4 2022.
Bioventus (BVS) has 2 years of Cash from Discontinued Operations data on file, last reported at 2169000.0 in Q2 2023.
- For the quarter ending Q2 2023, Cash from Discontinued Operations changed N/A year-over-year to 2169000.0; the trailing twelve-month figure through Dec 2023 stood at 2169000.0 (down 1.83% YoY), and the FY2023 full-year result was 2169000.0, down 1.83% from the prior year.
- Cash from Discontinued Operations for Q2 2023 stood at 2169000.0, down from 1271000.0 in the prior quarter.
- Across five years, Cash from Discontinued Operations topped out at 859000.0 in Q4 2022 and bottomed at 2169000.0 in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Bioventus | 535.01 Mn | 544.52 Mn | 90.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 1, 2023 | -2.17 Mn |
| Apr 1, 2023 | -2.17 Mn |
| Dec 31, 2022 | -1.27 Mn |
| Dec 31, 2022 | -1.27 Mn |
| Oct 1, 2022 | -859,000.00 |
| Oct 1, 2022 | -859,000.00 |